RIPK3 and Patent ductus arteriosus: Specifically, it has been shown that in pancreatic ductal adenocarcinoma (PDA), when RIPK3 knockout tumor cells undergo necroptosis, soluble cytokines released bind to receptors on inflammatory cells, triggering an immunosuppressive tumor microenvironment and promoting the progression of PDA [13].